Islet Amyloid and Type 2 Diabetes Mellitus
Almost a century ago, in 1901, Eugene L. Opie described “hyaline degeneration of the islands of Langerhans” in the pancreas of patients with hyperglycemia (Figure 1). 1 A relation with diabetes mellitus was suggested, although at that time insulin had not yet been identified as an islet protein. The...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2000-08, Vol.343 (6), p.411-419 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 419 |
|---|---|
| container_issue | 6 |
| container_start_page | 411 |
| container_title | The New England journal of medicine |
| container_volume | 343 |
| creator | Höppener, Jo W.M Ahrén, Bo Lips, Cornelis J.M |
| description | Almost a century ago, in 1901, Eugene L. Opie described “hyaline degeneration of the islands of Langerhans” in the pancreas of patients with hyperglycemia (Figure 1).
1
A relation with diabetes mellitus was suggested, although at that time insulin had not yet been identified as an islet protein. The chief component of the proteinaceous deposits described by Opie — later referred to as islet amyloid — was identified in 1986 as a protein of beta-cell origin named islet amyloid polypeptide.
2
Islet amyloid is a characteristic pathological finding in patients with type 2 diabetes mellitus, being present in more than 90 percent. . . . |
| doi_str_mv | 10.1056/NEJM200008103430607 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71291078</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>57732207</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-5ba03799ebdcae4d6734293125b458b2d4ef6c62fbb1ebb1e88c7ba1b05cb7f63</originalsourceid><addsrcrecordid>eNp9kEtLw0AUhQdRbI3-AkGCiAslOs9MZllq1Uqrm7oeZiY3kJJHzSSL_ntTU1BEvHC5m--cezgInRN8R7CI719nL0uK-0kIZpzhGMsDNCaCsYhzHB-iMcY0ibhUbIROvF_vWMLVMRoRrBiTnIzRzdwX0IaTclvUeRqaKg1X2w2ENHzIjYUWfLiEosjbzp-io8wUHs72N0Dvj7PV9DlavD3Np5NF5HiC20hYg5lUCmzqDPA0loxTxQgVlovE0pRDFruYZtYS2G2SOGkNsVg4K7OYBeh68N009UcHvtVl7l0fwlRQd15LQhXBMunBy1_guu6aqs-mKWVKUNkXEyA2QK6pvW8g05smL02z1QTrXY_6jx571cXeurMlpD80Q3E9cLUHjHemyBpTudx_c1x82QXodsDK0usK1uW_Xz8BKPaDrQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223952710</pqid></control><display><type>article</type><title>Islet Amyloid and Type 2 Diabetes Mellitus</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine Current</source><creator>Höppener, Jo W.M ; Ahrén, Bo ; Lips, Cornelis J.M</creator><creatorcontrib>Höppener, Jo W.M ; Ahrén, Bo ; Lips, Cornelis J.M</creatorcontrib><description>Almost a century ago, in 1901, Eugene L. Opie described “hyaline degeneration of the islands of Langerhans” in the pancreas of patients with hyperglycemia (Figure 1).
1
A relation with diabetes mellitus was suggested, although at that time insulin had not yet been identified as an islet protein. The chief component of the proteinaceous deposits described by Opie — later referred to as islet amyloid — was identified in 1986 as a protein of beta-cell origin named islet amyloid polypeptide.
2
Islet amyloid is a characteristic pathological finding in patients with type 2 diabetes mellitus, being present in more than 90 percent. . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM200008103430607</identifier><identifier>PMID: 10933741</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Amyloid - antagonists & inhibitors ; Amyloid - chemistry ; Amyloid - genetics ; Amyloid - physiology ; Amyloidosis - complications ; Amyloidosis - prevention & control ; Animals ; Biological and medical sciences ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - etiology ; Diabetes Mellitus, Type 2 - pathology ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Humans ; Insulin ; Insulin resistance ; Islet Amyloid Polypeptide ; Islets of Langerhans - pathology ; Medical sciences ; Mice ; Mice, Transgenic ; Pancreatic Diseases - complications ; Pancreatic Diseases - prevention & control ; Proteins</subject><ispartof>The New England journal of medicine, 2000-08, Vol.343 (6), p.411-419</ispartof><rights>Copyright © 2000 Massachusetts Medical Society. All rights reserved.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-5ba03799ebdcae4d6734293125b458b2d4ef6c62fbb1ebb1e88c7ba1b05cb7f63</citedby><cites>FETCH-LOGICAL-c480t-5ba03799ebdcae4d6734293125b458b2d4ef6c62fbb1ebb1e88c7ba1b05cb7f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM200008103430607$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM200008103430607$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1450810$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10933741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Höppener, Jo W.M</creatorcontrib><creatorcontrib>Ahrén, Bo</creatorcontrib><creatorcontrib>Lips, Cornelis J.M</creatorcontrib><title>Islet Amyloid and Type 2 Diabetes Mellitus</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Almost a century ago, in 1901, Eugene L. Opie described “hyaline degeneration of the islands of Langerhans” in the pancreas of patients with hyperglycemia (Figure 1).
1
A relation with diabetes mellitus was suggested, although at that time insulin had not yet been identified as an islet protein. The chief component of the proteinaceous deposits described by Opie — later referred to as islet amyloid — was identified in 1986 as a protein of beta-cell origin named islet amyloid polypeptide.
2
Islet amyloid is a characteristic pathological finding in patients with type 2 diabetes mellitus, being present in more than 90 percent. . . .</description><subject>Amyloid - antagonists & inhibitors</subject><subject>Amyloid - chemistry</subject><subject>Amyloid - genetics</subject><subject>Amyloid - physiology</subject><subject>Amyloidosis - complications</subject><subject>Amyloidosis - prevention & control</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - etiology</subject><subject>Diabetes Mellitus, Type 2 - pathology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Humans</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Islet Amyloid Polypeptide</subject><subject>Islets of Langerhans - pathology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Pancreatic Diseases - complications</subject><subject>Pancreatic Diseases - prevention & control</subject><subject>Proteins</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kEtLw0AUhQdRbI3-AkGCiAslOs9MZllq1Uqrm7oeZiY3kJJHzSSL_ntTU1BEvHC5m--cezgInRN8R7CI719nL0uK-0kIZpzhGMsDNCaCsYhzHB-iMcY0ibhUbIROvF_vWMLVMRoRrBiTnIzRzdwX0IaTclvUeRqaKg1X2w2ENHzIjYUWfLiEosjbzp-io8wUHs72N0Dvj7PV9DlavD3Np5NF5HiC20hYg5lUCmzqDPA0loxTxQgVlovE0pRDFruYZtYS2G2SOGkNsVg4K7OYBeh68N009UcHvtVl7l0fwlRQd15LQhXBMunBy1_guu6aqs-mKWVKUNkXEyA2QK6pvW8g05smL02z1QTrXY_6jx571cXeurMlpD80Q3E9cLUHjHemyBpTudx_c1x82QXodsDK0usK1uW_Xz8BKPaDrQ</recordid><startdate>20000810</startdate><enddate>20000810</enddate><creator>Höppener, Jo W.M</creator><creator>Ahrén, Bo</creator><creator>Lips, Cornelis J.M</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20000810</creationdate><title>Islet Amyloid and Type 2 Diabetes Mellitus</title><author>Höppener, Jo W.M ; Ahrén, Bo ; Lips, Cornelis J.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-5ba03799ebdcae4d6734293125b458b2d4ef6c62fbb1ebb1e88c7ba1b05cb7f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Amyloid - antagonists & inhibitors</topic><topic>Amyloid - chemistry</topic><topic>Amyloid - genetics</topic><topic>Amyloid - physiology</topic><topic>Amyloidosis - complications</topic><topic>Amyloidosis - prevention & control</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - etiology</topic><topic>Diabetes Mellitus, Type 2 - pathology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Humans</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Islet Amyloid Polypeptide</topic><topic>Islets of Langerhans - pathology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Pancreatic Diseases - complications</topic><topic>Pancreatic Diseases - prevention & control</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Höppener, Jo W.M</creatorcontrib><creatorcontrib>Ahrén, Bo</creatorcontrib><creatorcontrib>Lips, Cornelis J.M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Höppener, Jo W.M</au><au>Ahrén, Bo</au><au>Lips, Cornelis J.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Islet Amyloid and Type 2 Diabetes Mellitus</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2000-08-10</date><risdate>2000</risdate><volume>343</volume><issue>6</issue><spage>411</spage><epage>419</epage><pages>411-419</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Almost a century ago, in 1901, Eugene L. Opie described “hyaline degeneration of the islands of Langerhans” in the pancreas of patients with hyperglycemia (Figure 1).
1
A relation with diabetes mellitus was suggested, although at that time insulin had not yet been identified as an islet protein. The chief component of the proteinaceous deposits described by Opie — later referred to as islet amyloid — was identified in 1986 as a protein of beta-cell origin named islet amyloid polypeptide.
2
Islet amyloid is a characteristic pathological finding in patients with type 2 diabetes mellitus, being present in more than 90 percent. . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>10933741</pmid><doi>10.1056/NEJM200008103430607</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2000-08, Vol.343 (6), p.411-419 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71291078 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine Current |
| subjects | Amyloid - antagonists & inhibitors Amyloid - chemistry Amyloid - genetics Amyloid - physiology Amyloidosis - complications Amyloidosis - prevention & control Animals Biological and medical sciences Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - etiology Diabetes Mellitus, Type 2 - pathology Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Humans Insulin Insulin resistance Islet Amyloid Polypeptide Islets of Langerhans - pathology Medical sciences Mice Mice, Transgenic Pancreatic Diseases - complications Pancreatic Diseases - prevention & control Proteins |
| title | Islet Amyloid and Type 2 Diabetes Mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T13%3A38%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Islet%20Amyloid%20and%20Type%202%20Diabetes%20Mellitus&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=H%C3%B6ppener,%20Jo%20W.M&rft.date=2000-08-10&rft.volume=343&rft.issue=6&rft.spage=411&rft.epage=419&rft.pages=411-419&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM200008103430607&rft_dat=%3Cproquest_cross%3E57732207%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223952710&rft_id=info:pmid/10933741&rfr_iscdi=true |